Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cingulate Inc ( (CING) ) just unveiled an update.
On July 21, 2025, Cingulate Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing Lincoln Park to purchase up to $25 million of Cingulate’s common stock over a 36-month period. This agreement provides Cingulate with financial flexibility to support its regulatory approval processes, development, manufacturing, and commercialization activities, particularly for its product CTx-1301, and to fund general corporate purposes. The arrangement allows Cingulate to control the timing and amount of stock sales, with Lincoln Park obligated to purchase as directed, subject to certain conditions.
The most recent analyst rating on (CING) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 156,808
Technical Sentiment Signal: Hold
Current Market Cap: $21.95M
For an in-depth examination of CING stock, go to TipRanks’ Overview page.